Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 6, 2015, Pages 1306-1312

  Luxembourg, Alain ^a   Moreira, Edson D ^b   Samakoses, Rudiwilai ^c   Kim, Kyung Hyo ^d   Sun, Xiao ^a   Maansson, Roger ^a   Moeller, Erin ^a   Christiano, Susan ^a   Chen, Joshua ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^d Ewha Womans University School of Medicine   (South Korea)

Author keywords

HPV; Immunogenicity; Lot consistency; NCT 00943722; Vaccination; Vaccine

Indexed keywords

NINE VALENT HUMAN PAPILLOMAVIRUS L1 VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CROSS REACTION; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; HUMAN; IMMUNOASSAY; LICENSING; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VACCINATION; BIOSTATISTICS; BLOOD; IMMUNOLOGY; PROCEDURES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BIOSTATISTICS; CHILD; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UNITED STATES; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84944445804     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1009819     Document Type: Article

References (15)

1. Joura E, Giuliano A, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira E, Ngan Y, Petersen L, Lazcano E, et al. Efficacy of a 9-valent HPV vaccine against genital infection and intraepithelial neoplasia in women. New Engl J Med 2014; 372(8):711-23; PMID: 25693011.
2. Lachenbruch PA, Rida W, Kou J. Lot consistency as an equivalence problem. J Biopharm Stat 2004; 14:275- 90; PMID:15206526; http://dx. doi. org/10. 1081/BIP- 120037179
3. Marshall V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. Pediatrics 2011; 127 Suppl 1:S23-S30; PMID:21502242; http:// dx. doi. org/10. 1542/peds. 2010-1722E
4. US Food and Drug Administration CfBR. Guidance for industry for the evaluation of combination vaccines for preventable disease: production, testing and clinical studies. http://www. fda. gov/downloads/biologicsblood vaccines/guidancecomplianceregulatoryinformation/gui dances/vaccines/UCM175909. pdf. 1997.
5. World Health Organization. Clinical considerations for evaluation of vaccines for prequalification. http://www. who. int/immunization_standards/vaccine_quality_con siderations_oct10. pdf. 2010.
6. European Medicines Agency - Committee for human medicinal products. Note for guidance on the clinical evaluation of vaccines. http://www. ema. europa. eu/ docs/en_GB/document_library/scientific_guideline/ 2009/09/WC500003875. pdf. 2005.
7. Wang WW, Mehrotra DV, Chan IS, Heyse JF. Statistical considerations for noninferiority/equivalence trials in vaccine development. J Biopharm Stat 2006; 16:429-41; PMID:16892905; http://dx. doi. org/ 10. 1080/10543400600719251
8. Van Damme P. Immunogenicity and safety of a novel 9-valent hpv vaccine in girls 9-15 years of age compared to the quadrivalent vaccine. EUROGIN 2013, November 3-6 Available at http://www. eurogincom/ 2013/indexphp/abstracts/eurogin-2013-abstracts2014. Accessed January 12, 2014. 2014.
9. Roberts C, Hess E, Matys K, Brown M, Haupt R, Luxembourg A, Vuocolo S, Saah A, Antonello J, Green T. Development of a human papillomavirus competitive luminex immunoassay for nine HPV types. Hum Vaccin Immunother 2014; 10(8):2174-103; PMID: 25424920
10. Brown MJ, Seitz H, Towne V et al. Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 21:587-593, 2014
11. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
12. Ganju J, Izu A, Anemona A. Sample size for equivalence trials: a case study from a vaccine lot consistency trial. Stat Med 2008; 27:3743-54; PMID:18416439; http://dx. doi. org/10. 1002/sim. 3273
13. Sun X, Li X, Chen J. Comments on 'Sample size for equivalence trials: a case study from a vaccine lot consistency trial' by J. Ganju, A. Izu and A. Anemona. Stat Med 2012; 31:1652-3; PMID:22711252; http://dx. doi. org/10. 1002/sim. 4408
14. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines-immune responses. Vaccine 2012;30 Suppl 5:F83-F87.
15. Brown D, Muller M, Sehr P et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomavirus types 16 and 18. Vaccine 32:5880-5887, 2014.